Pulmonary Fibrosis Clinical Trials

106 recruitingLast updated: June 17, 2026

There are 106 actively recruiting pulmonary fibrosis clinical trials across 50 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1. Top locations include Los Angeles, California, United States, Kansas City, Kansas, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Pulmonary Fibrosis Trials at a Glance

106 actively recruiting trials for pulmonary fibrosis are listed on ClinicalTrialsFinder across 6 cities in 50 countries. The largest study group is Phase 2 with 29 trials, with the heaviest enrollment activity in Los Angeles, Kansas City, and Boston. Lead sponsors running pulmonary fibrosis studies include Avalyn Pharma Inc., Boehringer Ingelheim, and Erasmus Medical Center.

Browse pulmonary fibrosis trials by phase

Treatments under study

About Pulmonary Fibrosis Clinical Trials

Looking for clinical trials for Pulmonary Fibrosis? There are currently 29 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pulmonary Fibrosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pulmonary Fibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 106 trials

Recruiting

Role of Genetic Factors in the Development of Lung Disease

AsthmaCystic FibrosisPulmonary Fibrosis+2 more
National Heart, Lung, and Blood Institute (NHLBI)3,500 enrolled2 locationsNCT00001532
Recruiting
Phase 2

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Mediar Therapeutics164 enrolled69 locationsNCT06967805
Recruiting
Phase 3

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled373 locationsNCT06238622
Recruiting
Phase 2

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
Contineum Therapeutics324 enrolled22 locationsNCT07284459
Recruiting
Phase 2

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim71 enrolled46 locationsNCT07036523
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Interstitial Lung DiseasesFamilial Pulmonary FibrosisInterstitial Lung Abnormalities
Boehringer Ingelheim80 enrolled56 locationsNCT07201922
Recruiting

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

SarcoidosisIdiopathic Pulmonary FibrosisInterstitial Lung Diseases+1 more
University of Chicago4,000 enrolled1 locationNCT00470327
Recruiting
Phase 3

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Progressive Pulmonary FibrosisInterstitial Lung Disease
United Therapeutics698 enrolled159 locationsNCT05943535
Recruiting
Phase 2

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics120 enrolled16 locationsNCT06968845
Recruiting
Phase 1

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
University of Alabama at Birmingham10 enrolled1 locationNCT04362644
Recruiting
Not Applicable

Implementation of Home Monitoring in Patients With Pulmonary Fibrosis

Pulmonary FibrosisInterstitial Lung Disease (ILD)
Erasmus Medical Center220 enrolled11 locationsNCT06883448
Recruiting
Not Applicable

Skeletal Muscle Function in Interstitial Lung Disease

Interstitial Lung DiseaseIdiopathic Pulmonary FibrosisScleroderma+2 more
University of British Columbia40 enrolled1 locationNCT03800017
Recruiting
Phase 1

A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants

Idiopathic Pulmonary Fibrosis
Endeavor Biomedicines, Inc.57 enrolled2 locationsNCT07454291
Recruiting
Not Applicable

Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
Assiut University1,000 enrolled2 locationsNCT05842681
Recruiting
Phase 2

Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Dragonboat Biopharmaceutical Company Limited96 enrolled1 locationNCT07447102
Recruiting
Phase 2

Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease

Idiopathic Pulmonary FibrosisPulmonary Fibrosis, Interstitial Lung Disease
Vejle Hospital140 enrolled5 locationsNCT06714123
Recruiting

P4O2 ILD Extension

Interstitial Lung DiseasePulmonary FibrosisIPF+7 more
Amsterdam UMC, location VUmc450 enrolled1 locationNCT06644144
Recruiting

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Duke University3,000 enrolled44 locationsNCT01915511
Recruiting
Phase 2

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

Interstitial Lung DiseasePulmonary Fibrosis
Peter Caravan15 enrolled1 locationNCT07572383
Recruiting
Phase 1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Mannkind Corporation24 enrolled9 locationsNCT07344558